CRN09682

Table of contents

• What is CRN09682?
• How does CRN09682 work?
• Which conditions is it studied for?
• How is CRN09682 given?
• What do the clinical trials show?
• What side effects are known?

What is CRN09682?

CRN09682 is a chemically synthesised substance being developed as a potential medicine for certain cancers. It is classified in the therapeutic area of neoplasms (cancers).^[1] The substance is supplied by Crinetics Pharmaceuticals, Inc. and has no marketing authorisation in the product records, meaning it is an investigational substance still under study.^[1]

How does CRN09682 work?

The available registry data does not describe the mechanism of action of CRN09682. The trial focuses on tumours that express SST2, a protein found on the surface of certain cancer cells, which suggests the substance may target cells carrying this protein.

Which conditions is it studied for?

• Metastatic or locally advanced SST2-positive neuroendocrine neoplasms — tumours that arise from hormone-producing cells and have spread or cannot be removed by surgery, and carry the SST2 protein.
• Other SST2-positive solid tumours — additional types of solid cancers that also express SST2 and have relapsed or are resistant to previous treatment.

How is CRN09682 given?

CRN09682 is prepared as a solution for injection and is given by intravenous administration, meaning it is delivered directly into a vein.^[1]

What do the clinical trials show?

One authorised Phase 1/2 trial is investigating CRN09682 in 143 planned participants.^[1] The study has two parts: a dose escalation phase and a dose expansion phase.

In the dose escalation phase, the trial assesses the safety and tolerability of CRN09682 in participants with progressive SST2-expressing neuroendocrine neoplasms or other SST2-expressing relapsed or refractory solid tumours.^[1] The main measures include the incidence and severity of dose-limiting toxicities (DLTs), which are side effects severe enough to prevent increasing the dose, as well as adverse events and serious adverse events at each dose level.^[1]

In the dose expansion phase, the trial assesses safety and tolerability at the dose selected for expansion.^[1] The main measures include the nature, incidence and severity of adverse events and serious adverse events at the expansion dose, and interruptions at that dose.^[1]

What side effects are known?

No side effect data are available from the provided sources. The trial is designed to measure the incidence and severity of adverse events and serious adverse events, which will provide this information.^[1]